Uncategorized

J&J hands lymphoma bispecific CAR T back to AbelZeta

Published

on

Johnson & Johnson secured rights to prizlon-cel in 2023 for $245 million upfront. The asset in June last year showed a 100% response rate as a second-line option in a Phase 1b study for 10 patients with relapsed or refractory large B cell lymphoma.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version